Cardiology
ECG, ambulatory signals, hemodynamics, and rapid biomarkers.
Application before catalog
Compare the measurement, workflow, interface, and lifecycle questions that change from a central laboratory to a bedside or home setting.
Twelve decision environments
ECG, ambulatory signals, hemodynamics, and rapid biomarkers.
Continuous glucose data, adherence, alarms, and longitudinal review.
High-throughput chemistry, immunoassay, QC, and automation.
Point-of-care speed, operator competency, and result reconciliation.
Continuous monitoring, alarm priorities, battery, and network resilience.
Compact workflows, referral thresholds, and decentralized testing.
Detection limit, specimen pathway, biosafety, and reporting.
Traceability, repeat algorithms, QC, and donor safety workflows.
Perioperative monitoring, sterility, inventory, and escalation.
Setup, caregiver training, adherence, and connectivity fallback.
Medication-related monitoring, data access, and counseling workflow.
Data governance, equity, enrollment, and follow-up completion.
Method trade-offs
A centralized core laboratory can favor automation and statistical control; distributed point-of-care testing can favor minutes-to-result and reduced transport. Neither route is universally superior.
| Setting | Typical system | Evidence to verify | Material limitation |
|---|---|---|---|
| Core laboratory | Chemistry or immunoassay analyzer | 600–2,000 tests/hour planning band, coefficient of variation (CV), limit of detection (LOD), calibration, LIS | Transport and batching may delay urgent decisions |
| Point of care | Near-patient diagnostic instrument | Operator competency, QC lockout, result identity, minutes-to-result | Decentralized QC and lot control require governance |
| Critical care | Multi-parameter monitor | SpO2 labeled accuracy, alarm priority, 8-hour battery benchmark, reconnect | Motion, perfusion, alarm load, and network loss affect use |
| Home monitoring | Wearable or connected sensor | Pairing, adherence, data completeness, HL7 FHIR messaging, support path | Connectivity and caregiver capability vary outside hospital control |
| Infection control | Single-use or reprocessed device pathway | Unique device identification (UDI), lot, IFU, sterility assurance level (SAL), reprocessing validation | Single use increases waste; reuse adds labor and process risk |
Automation can improve consistency, QC traceability, menu breadth, and cost per test at scale. The trade-off is transport, batching, and dependence on the core facility.
Near-patient results can shorten the decision path and remove transport steps. The trade-off is distributed training, external quality assessment, operator lockout, and local inventory control.
Start with setting, users, volume, interface, market, and validation method.
Review product families